Familial pterygium of the conjunctiva
fuh-MIL-ee-uhl tuh-RIJ-ee-um of the kon-JUNK-tih-vuh
Also known as: Winglets of the eye, Conjunctival pterygium
At a Glance
What is Familial pterygium of the conjunctiva?
Familial pterygium of the conjunctiva is a rare genetic eye condition characterized by the growth of a benign, wing-shaped fibrovascular tissue on the conjunctiva, which is the clear tissue covering the white part of the eye. This condition primarily affects the eyes, leading to vision problems if the growth extends over the cornea. It is caused by genetic mutations that are inherited in an autosomal dominant pattern, meaning a single copy of the altered gene can cause the disorder. Over time, the pterygium can become more pronounced, potentially leading to discomfort, redness, and visual impairment. Early symptoms may include a small, raised area on the conjunctiva, while later stages can involve significant tissue growth and vision obstruction. Early diagnosis is crucial to manage symptoms and prevent progression that could lead to vision loss. The condition can impact family life due to its hereditary nature, possibly affecting multiple family members. Prognosis varies; some individuals may experience mild symptoms, while others may require surgical intervention. Daily life for affected individuals may involve regular eye examinations, protective eyewear, and possibly surgery to remove the growth. Despite its challenges, with proper management, individuals can maintain a good quality of life. Awareness and understanding of the condition within families can aid in early detection and treatment. Genetic counseling may be beneficial for affected families to understand inheritance patterns and risks.
Medical Definition
Familial pterygium of the conjunctiva is a genetic disorder characterized by the growth of fibrovascular tissue on the conjunctiva, often extending onto the cornea. Pathologically, it involves the proliferation of fibroblasts and altered expression of growth factors, contributing to tissue growth. Histologically, the pterygium shows elastotic degeneration of collagen and an inflammatory infiltrate. It is classified as an ocular surface disorder and is considered a rare disease with autosomal dominant inheritance. Epidemiologically, it is more prevalent in individuals with a family history of the condition, suggesting a strong genetic component. The disease course can vary, with some individuals experiencing slow progression and others requiring surgical intervention to prevent vision impairment.
Familial pterygium of the conjunctiva Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Eye irritation manifests as a persistent feeling of discomfort or grittiness in the eye. This is caused by the growth of fibrovascular tissue over the conjunctiva, leading to inflammation. Over time, the irritation may worsen as the pterygium enlarges and becomes more inflamed. Patients often experience difficulty in focusing and may require lubricating eye drops to alleviate symptoms.
Redness of the eye occurs due to increased vascularization and inflammation of the conjunctiva. The biological mechanism involves dilation of blood vessels in response to the invading tissue. As the condition progresses, the redness can become more pronounced and persistent. This symptom can affect a patient's appearance and may require anti-inflammatory medications to manage.
Blurred vision is a result of the pterygium encroaching onto the cornea, distorting its shape. This distortion affects the refraction of light entering the eye, leading to visual impairment. Over time, the blurring can become more severe as the pterygium grows. Patients may find it difficult to perform tasks requiring clear vision, such as reading, and corrective lenses or surgical intervention may be necessary.
Common
Foreign body sensation is the feeling that something is in the eye when there is nothing there. This sensation is caused by the irregular surface of the pterygium rubbing against the eyelid. As the pterygium grows, this sensation can become more frequent and bothersome. Patients often resort to blinking excessively or using artificial tears to relieve the discomfort.
Dry eyes occur when the tear film is disrupted by the presence of the pterygium. The biological mechanism involves reduced tear production or increased evaporation due to the altered ocular surface. Over time, dryness can lead to further irritation and inflammation. Patients may need to use lubricating eye drops regularly to maintain comfort and prevent complications.
Astigmatism arises when the pterygium induces an irregular curvature of the cornea. This irregularity causes light to focus unevenly on the retina, leading to blurred or distorted vision. As the pterygium progresses, the degree of astigmatism can increase, exacerbating visual disturbances. Corrective lenses or surgical removal of the pterygium may be required to restore normal vision.
Less Common
Eye pain can occur when the pterygium becomes inflamed or infected. The pain is due to the pressure exerted by the growing tissue on surrounding structures. Over time, the pain may become more intense, especially if complications arise. Pain management may involve the use of analgesics or anti-inflammatory medications.
Photophobia, or sensitivity to light, occurs when the inflamed tissue of the pterygium irritates the eye. This condition is caused by the increased exposure of nerve endings in the eye to light. As the pterygium enlarges, photophobia can become more pronounced, making it difficult for patients to be in bright environments. Wearing sunglasses and avoiding direct sunlight can help manage this symptom.
What Causes Familial pterygium of the conjunctiva?
Familial pterygium of the conjunctiva is associated with mutations in the gene TP53, located on chromosome 17p13.1. TP53 encodes the tumor protein p53, which plays a critical role in regulating the cell cycle and maintaining genomic stability. Mutations in TP53 can lead to a loss of function or gain of function, disrupting its ability to control cell proliferation and apoptosis. This disruption results in uncontrolled cell growth and resistance to cell death, promoting fibrovascular proliferation in the conjunctiva. The accumulation of abnormal fibroblasts and extracellular matrix components leads to the formation of the pterygium. Inflammatory mediators are released, attracting immune cells and causing chronic inflammation. This immune response can exacerbate tissue damage and fibrosis, contributing to the progression of the condition. Neuroinflammation may further impact local nerve cells, although its exact role in pterygium is not fully understood. Degeneration of conjunctival tissue and potential involvement of corneal structures occur as the pterygium advances. Symptoms such as redness, irritation, and visual impairment appear due to the encroachment of the pterygium onto the cornea. The pattern of symptom appearance is influenced by environmental factors like UV exposure, which exacerbates the condition. Disease severity varies between patients due to genetic heterogeneity, environmental influences, and differences in immune response. Variability in the expression of growth factors and cytokines also contributes to the differing clinical presentations. Understanding these molecular and cellular mechanisms is crucial for developing targeted therapies for familial pterygium.
How is Familial pterygium of the conjunctiva Diagnosed?
Typical age of diagnosis: Familial pterygium of the conjunctiva is typically diagnosed in early adulthood, often during routine eye examinations or when patients present with visual disturbances. The condition is characterized by a wing-shaped fibrovascular growth on the conjunctiva that can extend onto the cornea. Diagnosis is often prompted by the presence of symptoms such as redness, irritation, or blurred vision. Family history is crucial as the condition follows a dominant inheritance pattern.
The clinician looks for characteristic wing-shaped fibrovascular growths on the conjunctiva. A detailed family history is important to identify any hereditary patterns. Physical examination focuses on the extent of conjunctival involvement and any corneal encroachment. This step helps in differentiating pterygium from other conjunctival lesions and directs further diagnostic testing.
Slit-lamp biomicroscopy is the primary imaging modality used to assess the pterygium. Specific abnormalities include the presence of fibrovascular tissue extending from the conjunctiva onto the cornea. These findings confirm the diagnosis by visualizing the extent and characteristics of the lesion. Imaging helps exclude differentials such as pinguecula or conjunctival neoplasms.
No specific laboratory tests are routinely ordered for pterygium diagnosis. However, inflammatory biomarkers may be assessed to evaluate underlying inflammation. Abnormal results might show elevated levels of cytokines or growth factors. These results guide the consideration of anti-inflammatory treatments or further genetic testing.
Genetic testing involves sequencing genes associated with connective tissue disorders. Mutations in genes related to fibrovascular proliferation may be identified. Results confirm the diagnosis by linking genetic mutations to the clinical phenotype. Genetic testing also informs family counseling regarding inheritance patterns and recurrence risks.
Familial pterygium of the conjunctiva Treatment Options
Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are commonly used. They work by reducing inflammation and fibrovascular growth. Specific drugs include topical diclofenac and prednisolone. Clinical evidence supports their efficacy in reducing symptoms and slowing progression. Limitations include potential side effects such as increased intraocular pressure and cataract formation with prolonged use.
Techniques involve the use of artificial tears and lubricating ointments. The therapeutic goal is to alleviate dryness and irritation associated with pterygium. Sessions involve daily application, with frequency adjusted based on symptom severity. Measurable outcomes include improved comfort and reduced redness. Long-term benefits include enhanced ocular surface health and prevention of further irritation.
Surgery is indicated for pterygium that causes significant visual impairment or cosmetic concerns. The procedure involves excising the fibrovascular tissue and may include conjunctival autografting. Expected benefits include improved vision and appearance. Risks include recurrence and complications such as infection or scarring. Post-operative care involves the use of anti-inflammatory medications and regular follow-up visits.
The care team includes ophthalmologists, genetic counselors, and psychologists. Interventions focus on managing symptoms, providing genetic counseling, and addressing psychosocial impacts. Psychosocial support strategies include counseling and support groups. Family education covers disease management and genetic implications. Long-term monitoring involves regular eye examinations and adjustment of treatment plans as needed.
When to See a Doctor for Familial pterygium of the conjunctiva
- Sudden loss of vision — this is an emergency because it may indicate severe progression or complications requiring immediate medical intervention.
- Severe eye pain — this could signify an acute condition or complication that needs urgent evaluation.
- Rapid swelling or redness of the eye — these symptoms could indicate an infection or other serious condition requiring prompt treatment.
- Persistent eye irritation — this may suggest worsening of the condition and should be evaluated by an eye specialist.
- Gradual vision changes — these could indicate progression of the condition and warrant a medical review.
- Frequent tearing or discharge — this might be a sign of infection or inflammation that needs medical attention.
- Mild eye redness — monitor for any increase in severity or additional symptoms.
- Occasional dryness of the eye — ensure adequate hydration and monitor for worsening symptoms.
Familial pterygium of the conjunctiva — Frequently Asked Questions
Is this condition hereditary?
Familial pterygium of the conjunctiva is inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to offspring if one parent is affected. De novo mutations are rare, as the condition is typically familial. Carriers of the gene will likely develop symptoms, so genetic counseling is recommended for affected families. Genetic counseling can help assess risks and discuss family planning options.
What is the life expectancy for someone with this condition?
Life expectancy is generally not affected by familial pterygium of the conjunctiva. Prognosis depends on the age of onset and severity of symptoms. Factors such as sun exposure can worsen outcomes, while protective eyewear may improve them. Mortality is not directly caused by this condition, but complications can affect quality of life. Treatment can alleviate symptoms, leading to a better quality of life.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a thorough eye examination by an ophthalmologist, often prompted by visible symptoms. The time from first symptoms to diagnosis can vary, but is generally quick once medical attention is sought. Ophthalmologists and geneticists may be consulted for comprehensive evaluation. Delayed diagnosis can occur if symptoms are mild or mistaken for other conditions. Diagnosis is confirmed through clinical examination and family history.
Are there any new treatments or clinical trials available?
Research is ongoing into treatments targeting the underlying mechanisms of pterygium, including proteasome inhibitors. Gene therapy and novel pharmacological approaches are being explored. ClinicalTrials.gov is a resource for finding relevant clinical trials. Discussing participation in trials with your doctor is important for understanding potential benefits and risks. New treatments may become available in the next few years as research progresses.
How does this condition affect daily life and activities?
Familial pterygium can impact vision, affecting mobility and self-care activities. Educational performance may be influenced if vision is impaired. Social and emotional challenges arise from visible eye changes and potential vision loss. Family members may experience a burden due to caregiving needs. Supportive measures, such as visual aids and counseling, can help manage these challenges.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved.
Zhao D, Zhao H, He Y et al. · Life Sci · 2021 · PMID: 33482188
- 2.Reproductive risk factors of pterygium in postmenopausal women: a nationwide study in the Republic of Korea.
Shin E, Lim DH, Chung TY et al. · Sci Rep · 2021 · PMID: 34127737
- 3.Increased importin 13 activity is associated with the pathogenesis of pterygium.
Xu K, Tao T, Jie J et al. · Mol Vis · 2013 · PMID: 23559854
- 4.Winglets of the eye: dominant transmission of early adult pterygium of the conjunctiva.
Hecht F, Shoptaugh MG · J Med Genet · 1990 · PMID: 2359104
- 5.[The abnormal expression of epidermal growth factor receptor family in pterygium].
Liu Z, Xie Y, Zhang M et al. · Zhonghua Yan Ke Za Zhi · 2000 · PMID: 11853633
- 6.Oculocutaneous manifestations in xeroderma pigmentosa.
Goyal JL, Rao VA, Srinivasan R et al. · Br J Ophthalmol · 1994 · PMID: 8199117
- 7.Pyroptosis in pterygium pathogenesis.
Sun N, Zhang H · Biosci Rep · 2018 · PMID: 29724886
- 8.Ocular pterygium--digital keloid dysplasia.
Abarca H, Mellgren AE, Trubnykova M et al. · Am J Med Genet A · 2014 · PMID: 25124224
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-03